Triptorelin reduces risk of ovarian failure due to chemotherapy for breast cancer. JAMA 2011; 306: 269-76
Glare, J. (summary)
http://www.nelm.nhs.uk/en/NeLM-Area/News/2011---July/20/Triptorelin-reduces-risk-of-ovarian-failure-due-to-chemotherapy-for-breast-cancer/
Breast cancer in younger women is less common, about 12% aged under 45 years, but they are at increased risk of an adverse outcome and therefore most will receive intensive systemic chemotherapy. This may cause early ovarian failure leading to premature menopause: it is estimated that each month of chemotherapy translates into 1.5 years of lost reproductive life. There are no proven standard strategies for preventing this toxicity, however experimental work and pilot studies suggest that suppressing ovarian function with a gonadotropin-releasing hormone (GnRH) analogue might be helpful. This trial examined the hypothesis.
